The sPP subtype was associated with slightly older age (65.9 vs. 63.1 years, p = 0.026), lower likelihood of never-smoker status (10.8% vs. 37.4%, p < 0.001), black race/ethnicity (10.8% vs 6.5%, p = 0.033), tumors with mucinous (42.9% vs. 17.4%, p = 0.005) and non-acinar (80.0% vs. 58.1%, p = 0.035) histology, non-metastatic tumors (69.1% vs 50.9%, p = 0.016), negativity for ALK/ROS1/MET/RET abnormalities (96.8% vs 86.6%, p = 0.003), and stage II disease (18.6% vs. 7.1%, p < 0.001). Here, ROS1 is linked to metastatic neoplasm.